Please assess the completion status of the following clinical trial:

Trial Title: Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Body weight between 125 and 299 lbs~* Confirmed diagnosis of HIV-1 infection by western blot or by a documented HIV-1 viral load~* Currently receiving ART and on ART for \> 1 year~* VL \< 50 copies/ml for ≥ 1 year, with at least 2 measurements in the previous year, 1 viral blip with VL\< 400 copies/ml allowed~* HIV viral load of \<50 copies/ml at screening.~* CD4 \>450 cells/µL at screening.~* A negative ECG if \>45yrs men/\>55yrs women years of age or if below these years of age but with two added risk factors for coronary artery disease \[smoking, hypertension (BP \>140/90 or on antihypertensive medications), low HDL (\<40 mg/dL), family history of premature CHD (\<55 yrs males/\<65 females)\] or a Framingham score \> 15% (men) or 10% (women))~Exclusion Criteria:~* Confirmed clinical history of developing resistance to ART regimens that resulted in treatment changes~* Receiving didanosine as part of the participant's ART regimen at the time of screening~* Ongoing treatment with Isoniazide, pyrazinamide, Rifabutin, Rifampicin, Diadenosine Ganciclovir, Valgancyclovir, Oxymetholone, Thalidomide or Theophylline.~* Use of any investigational drug within 30 days prior to screening~* History or current use of immunomodulatory therapy for over 2 weeks during the 6 months prior to enrollment, including, but not limited to: IFN-alpha or gamma (recombinant or pegylated), systemic corticosteroids (nasal or pulmonary steroids will be allowed; systemic cancer chemotherapy/irradiation; cyclosporin; tacrolimus (FK-506); OKT-3; any Interleukin, including IL-2; cyclophosphamide; methotrexate; IVIG (gamma globulin); G/M-CSF; hydroxyurea; thalidomide; pentoxifylline; thymopentin; thymosin; dithiocarbonate; polyribonucleotide.~* History of adverse or allergic reactions to any type-1 interferon (e.g. IFN-alpha2a, IFN-α2b, IFN-beta)~* History of severe depression, or ongoing moderate depression determined by PHQ-9 at screening~* Type I diabetes mellitus, or type II diabetes mellitus that is not controlled with oral agents and/or insulin.~* Prior diagnosis of multiple sclerosis or other neurodegenerative disorders~* Significant co-existing lab abnormalities including:~  1. Anemia (Hgb \<9.1 mg/dl men, \<8.9 mg/dl women)~ 2. WBC \<2000 cells/µl~ 3. Absolute neutrophil count (ANC) \<1200 cells/ µl~ 4. Platelet count \<60,000 cells/ µl~ 5. Liver disease (AST/ALT \> 2.5x, Total Bilirubin \> 1.5x upper limits of norm (ULN), or Total Bilirubin \>3x ULN if receiving indinavir OR Atazanavir)~ 6. Renal disease (creatinine \> 2x upper normal limits or creatinine clearance \<60mg/dl (by Crockoff-Gault)~* Chronic HCV infection (HCV viremia), or HBV Ag positive and/ or HBV viremia (Notice: subjects with prior HCV infection with a documented sustained virologic response with treatment finishing \>1 year prior to screening are eligible for enrollment).~* Liver cirrhosis or hepatic decompensation with Child Pugh score \> 6~* History of major organ transplantation with an existing functional graft.~* Evidence of OI or other active infectious diseases or active malignancies~* Active Autoimmune diseases, including autoimmune hepatitis~* History of retinopathy or clinically significant ophthalmologic disease on eye exam performed within 6 months prior to initiation of IFN~* Pregnancy, actively attempting to become pregnant, or breastfeeding~* Body weight under 125 lbs or over 300 lbs~* Other conditions, such as active drug/alcohol abuse or dependence which would interfere with study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interferon alpha (Type: EXPERIMENTAL): pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).